Evidence map›Paper›PMID 23548047›Full record

ArticleBMC immunology2013

Anti-tumor necrosis factor VNAR single domains reduce lethality and regulate underlying inflammatory response in a murine model of endotoxic shock.

Rafael Bojalil, María Teresa Mata-González, Fausto Sánchez-Muñoz, Yepci Yee, Iván Argueta, Lucía Bolaños, Luis Manuel Amezcua-Guerra, Tanya Amanda Camacho-Villegas, Edna Sánchez-Castrejón, Walter Jakob García-Ubbelohde and 3 more

Open access · goldAbstract read
In one paragraph

Article in BMC immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. VNAR development through antigen immunization of Japanese topeshark (Frontiers in bioengineering and biotechnology · 2023
    Article
  4. Article
  5. Article
  6. Article
  7. Bamboo Shark as a Small Animal Model for Single Domain Antibody Production.Frontiers in bioengineering and biotechnology · 2021
    Article
  8. Review
  9. Review
  10. Article
  11. Single Domain Antibodies as New Biomarker Detectors.Diagnostics (Basel, Switzerland) · 2017
    Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Rafael BojalilDepartment of Immunology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.
María Teresa Mata-González
Fausto Sánchez-Muñoz
Yepci Yee
Iván Argueta
Lucía Bolaños
Luis Manuel Amezcua-Guerra
Tanya Amanda Camacho-Villegas
Edna Sánchez-Castrejón
Walter Jakob García-Ubbelohde
Alexei Fedorovish Licea-Navarro
Ricardo Márquez-Velasco
Jorge Fernando Paniagua-Solís
Instituto Nacional de Cardiología · MXCenter for Scientific Research and Higher Education at Ensenada · MXGMV Innovating Solutions (Spain) · ESUniversidad Autónoma de Baja California · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn sepsis, tumor necrosis factor (TNF) is the key factor triggering respiratory burst, tissue injury and disseminated coagulation. Anti-TNF strategies based on monoclonal antibodies or F(ab')₂ fragments have been used in sepsis with contradictory results. Immunoglobulin new antigen receptors (IgNAR) are a unique subset of antibodies consisting of five constant (CNAR) and one variable domains (VNAR). VNAR domains are the smallest, naturally occurring, antibody-based immune recognition units, having potential use as therapy. Our aim was to explore the impact of an anti-TNF VNAR on survival in an experimental model of endotoxic shock. Also, mRNA expression and serum protein of several inflammatory molecules were measured.

resultsEndotoxic shock was induced by lipopolysaccharide (LPS) in male Balb/c mice. Animals were treated with anti-TNF VNAR domains, F(ab')₂ antibody fragments, or saline solution 15 minutes before, 2 h and 24 h after lethal dose₁₀₀ (LD₁₀₀) LPS administration. TNF blockade with either VNAR domains or F(ab')₂ fragments were associated with lower mortality (60% and 75%, respectively) compared to LD₁₀₀. Challenge with LPS induced significant production of serum TNF and interleukins -10 and -6 at 3 h. After that, significant reduction of IL-6 at 24 h (vs 3 h) was shown only in the VNAR group. Nitrites level also increased in response to LPS. In liver, TNF and IL-10 mRNA expression showed a pro-inflammatory imbalance in response to LPS. Blocking TNF was associated with a shift towards an anti-inflammatory status; however, polarization was more pronounced in animals receiving F(ab')₂ fragments than in those with VNAR therapy. With regard to IL-6, gene expression was increased at 3 h in all groups. TNF blockade was associated with rapid and sustained suppression of IL-6 expression, even more evident in the VNAR group. Finally, expression of inducible-nitric oxide synthase (iNOS) increased in response to LPS at 3 h, but this was decreased at 24 h only in the anti-TNF VNAR group.

conclusionsAnti-TNF VNAR single domains improved survival in a murine model of endotoxic shock. Protection was associated with regulation in the TNF/IL-10 balance, attenuation of IL-6 and iNOS gene expression in the liver as well as decreased serum IL-6 concentration.

Indexed as

AnimalsBiomarkersDisease Models, AnimalHumansInflammationInterleukin-10Interleukin-6LipopolysaccharidesLiverMaleMiceMice, Inbred BALB CNitratesNitric Oxide Synthase Type IIProtein Structure, TertiaryRNA, MessengerBiomarkersInterleukin-10Interleukin-6LipopolysaccharidesNitratesNitric Oxide Synthase Type IIRNA, MessengerSingle-Domain AntibodiesTumor Necrosis Factor-alpha

Identifiers

PMID23548047
PMCPMC3621089
OpenAlexW2167918070

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.